Latest H5N1 clinical trials Stories
BEIJING, Dec. 28, 2010 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.
QUEBEC CITY, QC, Dec. 22 /PRNewswire/ - Medicago Inc.
The costly, time-consuming process of making, distributing and administering millions of seasonal flu vaccines would become obsolete if researchers could design a vaccine that confers decades-long protection from any flu virus strain.
Only the fragile chicken egg stands between Americans and a flu pandemic that would claim tens of thousands more lives than are usually lost to the flu each year.
SWIFTWATER, Pennsylvania, November 29, 2010 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has started its phase II clinical study of a vaccine for primary prevention of Clostridium difficile infection (CDI).
ITTIGEN and BERN, Switzerland, November 11, 2010 /PRNewswire/ -- Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC). Also known as chronic recurrent thrush, RVVC is a highly debilitating condition, which affects an estimated 3-6% of women worldwide.
LYON, France, November 4, 2010 /PRNewswire-FirstCall/ -- - First Phase 3 Study Underway in Australia Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that its dengue vaccine is in final stage of clinical development.
PRINCETON, N.J., Nov. 2, 2010 /PRNewswire-FirstCall/ -- Soligenix, Inc.
QUEBEC CITY , Nov. 1 /PRNewswire/ - Medicago Inc.
SWIFTWATER, Pa., Oct.